Numbers
The Numbers
Daqo trades like a distressed cyclical despite a balance sheet that still looks overcapitalized: current market cap is $1.29B against FY2025 cash of $1.94B and no staged financial debt. The market is not paying for book value because the income statement has not proved that the polysilicon trough is over; the single metric most likely to rerate the stock is shipped volume at an ASP above total production cost.
Snapshot
Price
Market Cap
FY2025 Cash
Current P/B
The stock is cheap on asset value, not on current earnings power. FY2025 revenue fell 35.3% to $665M, operating margin was -40.6%, and Q1 2026 revenue collapsed to $26.7M.
Is this a well-run business that will still be around in 10 years?
The survival answer is yes because the balance sheet has room. The compounding answer is unproven because cash flow depends on a commodity spread Daqo does not control.
Revenue and Earnings Power
The 2022 peak was not a new steady state; it was a polysilicon price spike. By FY2025, revenue was back near 2020 levels while operating income was negative $270M.
Q1 2026 is the warning: production remained high, but reported revenue was only $26.7M because sales volume fell to 4,482 MT.
Cash Generation
Cash conversion looks better than earnings only because the denominator collapsed. Over FY2021-FY2025, Daqo generated about $4.33B of operating cash flow but only $986M of free cash flow after capex.
Capital Allocation
The company is not levered and does not have a dividend constraint. The allocation question is whether holding cash and inventory through the trough earns a higher return than returning capital.
Balance Sheet Health
Receivables more than doubled in FY2025 off a low base while revenue fell. That is not yet a balance-sheet crisis, but it belongs on the next-quarter checklist because weak sell-through can migrate into credit and inventory charges.
Valuation vs History
Current P/B
FY2025 Operating Margin
Net Cash
The valuation case is book-value and net-cash driven. A normal multiple on trough losses is not meaningful until pricing and volume normalize.
Peer Comparison
The staged peer data is qualitative, so the useful comparison is not a false precision multiple table. Daqo should be judged against the cost curve and balance-sheet endurance of the Chinese polysilicon set.
Fair Value and Scenario
The numbers confirm Daqo can survive the trough, contradict the idea that the Q4 2025 rebound settled the cycle, and make Q2/Q3 sell-through the next decisive test.